Adam Walker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adam Walker has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Andre L Moreira
Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine , New York, NY
1 shared publicationAndres Martin Acosta
Department of Pathology, Indiana University , Indianapolis, IN
1 shared publication- Arline Faustin
Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine , New York, NY
1 shared publication - Camila S. Fang
Department of Neurosurgery, NYU Langone Health, New York
1 shared publication Chanel Schroff
Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine , New York, NY
1 shared publicationChristopher M William
Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine , New York, NY
1 shared publication
Latest Publications
- Open Access
- 28 November 2024
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 84 (2) , 147-154
Deep learning-based classifier for carcinoma of unknown primary using methylation quantitative trait loci
Cancer of unknown primary (CUP) constitutes between 2% and 5% of human malignancies and is among the most common causes of cancer death in the United States. Brain metastases are often the first clinical presentation of CUP; despite extensive pathological and imaging studies, 20%-45% of CUP are never assigned a primary site. DNA methylation array profiling is a reliable method for tumor classification but tumor-type-specific classifier development requires many reference samples. This is difficult to accomplish for CUP as many cases are never assigned a specific diagnosis. Recent studies identified subsets of methylation quantitative trait loci (mQTLs) unique to specific organs, which could help increase classifier accuracy while requiring fewer samples. We performed a retrospective genome-wide methylation analysis of 759 carcinoma samples from formalin-fixed paraffin-embedded tissue samples using Illumina EPIC array. Utilizing mQTL specific for breast, lung, ovarian/gynecologic, colon, kidney, or testis (BLOCKT) (185k total probes), we developed a deep learning-based methylation classifier that achieved 93.12% average accuracy and 93.04% average F1-score across a 10-fold validation for BLOCKT organs. Our findings indicate that our organ-based DNA methylation classifier can assist pathologists in identifying the site of origin, providing oncologists insight on a diagnosis to administer appropriate therapy, improving patient outcomes.
- 28 November 2024
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 84 (2) , 147-154
Open AccessDeep learning-based classifier for carcinoma of unknown primary using methylation quantitative trait loci
Cancer of unknown primary (CUP) constitutes between 2% and 5% of human malignancies and is among the most common causes of cancer death in the United States. Brain metastases are often the first clinical presentation of CUP; despite extensive pathological and imaging studies, 20%-45% of CUP are never assigned a primary site. DNA methylation array profiling is a reliable method for tumor classification but tumor-type-specific classifier development requires many reference samples. This is difficult to accomplish for CUP as many cases are never assigned a specific diagnosis. Recent studies identified subsets of methylation quantitative trait loci (mQTLs) unique to specific organs, which could help increase classifier accuracy while requiring fewer samples. We performed a retrospective genome-wide methylation analysis of 759 carcinoma samples from formalin-fixed paraffin-embedded tissue samples using Illumina EPIC array. Utilizing mQTL specific for breast, lung, ovarian/gynecologic, colon, kidney, or testis (BLOCKT) (185k total probes), we developed a deep learning-based methylation classifier that achieved 93.12% average accuracy and 93.04% average F1-score across a 10-fold validation for BLOCKT organs. Our findings indicate that our organ-based DNA methylation classifier can assist pathologists in identifying the site of origin, providing oncologists insight on a diagnosis to administer appropriate therapy, improving patient outcomes.